The FDA has approved Genentech‘s Lunsumio (mosunetuzumab-axgb), a novel bispecific antibody for relapsed or refractory follicular lymphoma (R/R FL). The indication covers R/R FL patients who have received at least two prior systemic therapies. Patients with the cancer subtype have had limited treatment options and significant morbidity and mortality. The approval of Lunsumio is the…
Roche’s bispecific antibody Lunsumio wins priority review from FDA for non-Hodgkin lymphoma
Roche (SIX:RO, ROG; OTCQX:RHHBY) has announced that it has accepted the company’s Biologics License Application (BLA) and granted priority review for Lunsumio (mosunetuzumab), a CD20xCD3 T-cell engaging bispecific antibody developed by the company’s Genentech subsidiary. In February, Biogen (Nasdaq:BIIB) said it would pay $30 million to exercise an option to participate in the development and…